linjc16/ctgov huggingface dataset:
Electromiographic Analysis of the Quadriceps After Trauma

Study Overview
=================
Brief Summary
-----------------
The lower limb is the region most affected by fractures in the human body. The magnitude of the trauma can cause injuries to structures adjacent to the fracture, promoting joint instability and consequently predisposition to osteoarthritis. The treatment of fractures can be performed conservatively or surgically, and one of the consequences of the surgery is arthrogenic muscle inhibition, which presents itself as a marked muscle weakness due to inhibition of the central nervous system that prevents adequate muscle activation. However, recruiting the quadriceps is the most commonly used goal to determine the patient's return to activities. Physiotherapy has several resources for the functional activation of the quadriceps muscle, such as neuromuscular electrostimulation (NMES), verbal command of muscle activation and neuromatrix techniques. Thus, the objective of this study will be to analyze, by means of electromyography, the myoelectric activity of the quadriceps muscle in individuals undergoing physical therapy intervention, affected by some fracture of the lower limb.

Official Title
-----------------
Electromiographic Analysis of the Quadriceps in Individuals Undergoing Neuromuscular Electro-stimulation Intervention, Verbal Command and Neuromatrix

Conditions
-----------------
Leg Injury, Bone Fracture

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: trauma in lower member intervention Exclusion Criteria: neuromuscular disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| myoelectric activity of the quadriceps muscle<br>electromyography myoelectric activity of the quadriceps muscle | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| electromyography | will be performed an examination of electrical muscle conductance | one time - during the procedure | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| myoelectric activity of the quadriceps muscle | will be performed an examination of electrical muscle conductance | one time - during the procedure |
Fascia Iliaca Blocks and Pre-operative Opioid Requirements in Hip Fracture Patients

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine if non-continuous local anesthetic fascia iliaca blocks performed in the emergency department are effective for preoperative analgesia in hip fracture patients. Investigators hypothesize that patients with these blocks will have lower opioid requirements than patients in a historical group in whom blocks were not performed.

Official Title
-----------------
Pre-operative Fascia Iliaca Blocks and Opioid Requirements in Hip Fracture Patients

Conditions
-----------------
Hip Fracture

Intervention / Treatment
-----------------
* Other: Observational
* Other: Retrospective review


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: low energy femoral neck and pertrochanteric-type hip fractures age 65+ intact cognition upon admission and ability to provide written informed consent Exclusion Criteria: pathologic fractures (tumor) high energy fractures concomitant fractures besides hip fractures chronic home opioid exposure prior to hospitalization moderate to severe dementia pre-fracture hospitalization time from arrival to block >6 hours time from arrival to OR <6 hours or >48 hours

Ages Eligible for Study
-----------------
Minimum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Fascia Iliaca Block Cohort<br>Prospective patients receiving fascia iliaca blocks A prospective Observational study of Hip fracture patients that are offered fascia iliaca blocks as standard of care in the ED. | Other: Observational<br> <br> |
| Retrospective Control Cohort<br>No fascia iliaca block performed A retrospective review will be done of hip fracture patients that did not receive fascia iliaca blocks (before fascia iliaca blocks being offered in the ED as standard of care). | Other: Retrospective review<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Total Pre-op IV Morphine Equivalents (TIVME) | IV morphine equivalent dosing pre-operatively | From Date of admission until date of surgery, approximately 48 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean Pre-op Pain Score | Mean patient-reported pain score | From Date of admission until date of surgery, approximately 48 hours | 
| Length of Hospital Stay (LOS) |  | Through study completion, approximately 5 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
fascia iliaca blocks
Surgical Treatment of Obstructed Defecation Syndrome

Study Overview
=================
Brief Summary
-----------------
Obstructed Defecation is a profoundly disabling condition. Many different surgical procedures has been introduced to treat patients affected by this disease. The most used are STARR and ventral rectopexy. Because of the heterogenity of studies and overall the lack of comparison trials, there is no accepted standard surgical treatment.PRO-REST aimed to compare these two procedures (STARR and Ventral Rectopexy) evaluating functional and anatomical results.

Official Title
-----------------
Obstructed Defecation Caused by Rectal Intussusception and Rectocele:STARR Versus Laparoscopic Ventral Rectopexy

Conditions
-----------------
Sensation of Inadequate Defecation, Rectal Prolapse, Rectocele

Intervention / Treatment
-----------------
* Procedure: STARR
* Procedure: Laparoscopic Ventral Rectopexy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients affected by Obstructed Defecation with ODS score >11 Symptomatic rectal Intussusception and/or defecographic finding of rectocele>2 cm Failure of at least 6 months of medical therapy Exclusion of neoplasm by rectosigmoidoscopy/colonoscopy Exclusion Criteria: Patients affected by complete rectal prolapse Patients affected by slow transit constipation Patients affected by anismus Patients affected by pelvic organ prolapse Patients with previous rectal or anal surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Group A<br>STARR | Procedure: STARR<br> <br> |
| Experimental: Group B<br>Laparoscopic ventral Rectopexy | Procedure: Laparoscopic Ventral Rectopexy<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Functional result | comparison between Obstructed Defaecation Syndrome (ODS) score before and 12 months after surgery | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Anatomical result | Comparison of clinical and radiological data before and 12 months after surgery | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Obstructed Defecation, Rectal rectocele, Intussusception, STARR, Ventral Rectopexy
Systemic Nalbuphine Versus Intravenous Regional Anesthesia

Study Overview
=================
Brief Summary
-----------------
Comparison of systemic nalbuphine versus intravenous regional anesthesia in patients undergoing hand surgery.

Official Title
-----------------
Comparison of Systemic Nalbuphine Versus Intravenous Regional Anesthesia

Conditions
-----------------
Postoperative Pain

Intervention / Treatment
-----------------
* Drug: Systemic nalbuphine
* Drug: Local nalbuphine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients scheduled for elective unilateral hand surgery. Exclusion Criteria: Patient refusal. Allergy to study medications Body mass index > 35 kg/ m2 Patients with sickle cell or Reynaud diseases Patients with a history of psychiatric illness or on chronic opioids

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: Two groups
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Systemic nalbuphine group<br>53 patients will receive nalbuphine systemically | Drug: Systemic nalbuphine<br>* Patients will receive systemic nalbuphine 10 mg<br>|
| Active Comparator: Local nalbuphine group<br>53 patients will receive nalbuphine with local intravenous regional anesthesia (IVRA) | Drug: Local nalbuphine<br>* Patients will receive local nalbuphine 10 mg<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Duration of postoperative Analgesia | minutes | Postoperative 24 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Diclofenac analgesic consumption | mg | Postoperative 24 hours | 
| Cortisol level | Level of cortisone in blood (nmol/L) | Preoperative and at 4 hours after skin incision | 
| Severity of postoperative Pain | Visual Analogue Scale (VAS) | Postoperative 24 hours |
Mechanism and Predictor of Side Branch Jailing

Study Overview
=================
Brief Summary
-----------------
Coronary artery bifurcation lesion is still one of the most challenging lesion subsets in the field of non-surgical treatment for a stenotic coronary artery. When one stent is placed in the main brach, it increases the side branch's stenosis degree. However, its mechanism and incidence are not known. This study will be performed to search for the mechanism and incidence of that phenomenon.

Official Title
-----------------
Predictor and Mechanism of a Side Branch Jail After Main Branch Stent Implantation in Bifurcation Lesions

Conditions
-----------------
Bifurcating Coronary Artery Lesions, Main Branch Stent Implantation, Side Branch Jailing

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Elective coronary intervention (including stabilized ACS patients) Bifurcation lesion with TIMI 3 flow Side branch diameter > 2mm, side branch lesion length < 10mm by visual estimation Exclusion Criteria: Left main coronary disease AMI, or Old MI at LAD territory LVEF < 40%, or other significant valvular or myocardial disease Significant side branch distal lesion Angiographically visible thrombus Heavily calcified lesion Side branch predilatation before main branch stent implantation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Patients with elective coronary intervention for LAD-diagonal bifurcation lesion with provisional side branch intervention strategy with successful intravascular ultrasound and fractional flow reserve measurement | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
coronary artery, bifurcation, stent, intravascular ultrasound, fractional flow reserve
Study Evaluating the Efficacy and Safety With CD19CAR-T for Relapsed or Refractory Acute Lymphoblastic Leukemia

Study Overview
=================
Brief Summary
-----------------
This study is a single-arm, open label, phase I clinical trial to evaluate the safety and feasibility of CD19CAR-T in treatment of relapsed / refractory acute lymphoblasic leukemia.

Official Title
-----------------
Study Evaluating the Efficacy and Safety With CD19CAR-T for Relapsed or Refractory Acute Lymphoblastic Leukemia

Conditions
-----------------
Relapsed Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia

Intervention / Treatment
-----------------
* Combination Product: CD19 CART


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis with Relapsed or refractory acute lymphocyte leukemia with CD19 positive Age 18 to 65 years old, both male and female; Is expected to survive more than 12 weeks; Physical condition is good: 0-1 score ECOG score; No obvious abnormal heart, liver, kidney, no large wounds that haven't healed on the body; Into groups to participate in voluntarily, good adherence, can cooperate test observation, childbearing age women must be 7 days before starting treatment expert pregnancy test and the results were negative, and signed a written informed consent form. Exclusion Criteria: Organ failure, such as heart: Class III and IV; liver: to Child grading of liver function grade C; kidney: kidney failure and uremia stage; lung: symptoms of severe respiratory failure; brain: disorder of consciousness; Existing serious acute infection, uncontrollable, or have fester sex and chronic infection, wound in delay no more; Pregnancy and lactation women; Patients who have participated in other clinical trials or other clinical trials in the past 30 days; The Investigator believe the patients should not participate in this experiment.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: study group<br>After 6 days of pre-chemotherapy, patients in study group will be injected with CD19CART cell at the dose of 5×10^4 cells/kg in 36-96 hours | Combination Product: CD19 CART<br>* CD19 CART<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| recovery rate of patients being treated with CD19CAR-T | the recovery rate of patients consists of complete recovery rate and partial recovery rate of patients being treated with CD19 CAR-T | 6 months |
Medication Exposure in Older Patients With Constitutional Hemorrhagic Disease

Study Overview
=================
Brief Summary
-----------------
The improvements observed in the care of patients with hemophilia or Willebrand disease have led to an increase in their life expectancy, which today approaches that of the general population. This increase in life expectancy leads in these patients to the development of comorbidities related to aging (cardiovascular and neurological diseases, cancers and kidney diseases) (e.g Franchini & Mannuccio, BJH, 2009). The care of these comorbidities represents a new challenge for the medical teams. Toward multiple comorbidities, polypharmacy is often associated. Many studies about medication exposure and management in older patients were published but no study was conducted to explore the medication management of older patients with hemophilia or Willebrand disease.

Official Title
-----------------
Medication Exposure in Older Patients (AGEd > 65 Years) With Constitutional HEMORRHagic Disease (Haemophilia or Willebrand Disease).

Conditions
-----------------
Hemophilia

Intervention / Treatment
-----------------
* Other: Telephone interview


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Community-dwelling patients over 65 years with hemophilia (A or B) Community-dwelling patients over 65 years with Willebrand disease (Type1, 2 and 3, rate <30%) Exclusion Criteria: Patients without phone number Non French speaking patients

Ages Eligible for Study
-----------------
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Telephone interview|Primary objective: potentially inappropriate medication prevalence Secondary objective: Number and type of medication Polypharmacy prevalence Medication regimen complexity using Medication Regimen Complexity Index Anticholinergic and sedative exposure using Drug Burden Index A telephone interview will be conducted with patients in order to collect medication data from medical prescriptions.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Potentially inappropriate medication (PIM) prevalence using EU-(7) PIM list. | A telephone interview will be conducted with patients in order to collect medication data from medical prescriptions. After collection of data for all patients, the research of PIM was conducted. | At inclusion | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Willebrand disease
The Relationship Between Sleep Disorders and Cytokine Levels Among Hemodialysis and Peritoneal Dialysis Patients

Study Overview
=================
Brief Summary
-----------------
Sleep disorders are common in patients with end-stage renal disease on both hemodialysis and peritoneal dialysis and are associated with significant medical, psychological and social disturbances. Numerous factors have been suggested as contributing to or associated with the high prevalence of sleep disturbance in this population. Increasing evidence suggests that cytokines are involved in the regulation of sleep and wakefulness and that the communication between the sleep and the immune system is bi-directional. Blood-dialyzer or peritoneum-dialysate interaction during dialysis therapy has the potential to activate mononuclear cells leading to production of inflammatory cytokines. These cytokines are believed to play a significant role in dialysis-associated morbidity and mortality. Nevertheless, a cytokine overproduction may alter sleep pattern in chronic dialyzed patients, thus explaining the presence of sleep disorders in these patients. In the other way, sleep loss may have effects on immune process and secretion of cytokines in chronic dialyzed patients. The purpose of this study was to examine the relationship between quality of sleep and serum cytokine levels in hemodialysis and peritoneal dialysis patients.

Conditions
-----------------
Renal Failure, Sleep Disorder, Hemodialysis, Peritoneal Dialysis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ESRD Patients with hemodialysis or peritoneal dialysis Exclusion Criteria: Malignancy, hospitalization, infection, inflammation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
The Role of Vitamin D3 and Calcium Supplementation in Attenuating T2DM Severity

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate the effect of vitamin D3 and calcium supplementation in attenuating type 2 diabetes mellitus outcomes in ethnic diverse, diabetic patiens.

Detailed Description
-----------------
Subjects of this study received a total of 1800 IU vitamin D3 and 720 mg of calcium per day for 3 years. The study was conducted in Toronto, Ontario, Canada.

Official Title
-----------------
The Role of Vitamin D and Calcium Supplementation in the Pathogenesis of Type 2 Diabetes Mellitus

Conditions
-----------------
Type 2 Diabetes Mellitus

Intervention / Treatment
-----------------
* Dietary Supplement: vitamin D3 and calcium
* Other: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Type 2 diabetes mellitus Non-white, post menopausal female Have access to Community Health Center Exclusion Criteria: neurodegenerative disease kideny disease gluten allergy

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: CaD Group<br>This arm received total of 1800 IU of vitamin D3 and 720 mg of calcium | Dietary Supplement: vitamin D3 and calcium<br>* 1800 IU vitamin D3 plus 720 mg Calcium<br>|
| Placebo Comparator: Placebo Group<br>This arm received rice powder pills | Other: Placebo<br>* Rice powder pills<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Serum calcidiol |  | 3 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Fasting insulin |  | 3 years | 
| Parathyroid Hormone |  | 3 years | 
| Fasting blood glucose |  | 3 years | 
| Glycated Hemoglobin |  | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
serum calcidiol, T2DM, vitamin D3 supplementation, post-menopausal women, ethnic diverse, calcium supplementation